trending Market Intelligence /marketintelligence/en/news-insights/trending/d-XJVDk1fIybDEa4QulRqA2 content esgSubNav
In This List

Bio-Rad files new patent suit against 10X Genomics

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Bio-Rad files new patent suit against 10X Genomics

Bio-Rad Laboratories Inc. filed a lawsuit against 10x Genomics Inc. for allegedly infringing a patent licensed exclusively to Bio-Rad from Harvard University and the Medical Research Council.

Hercules, Calif.-based Bio-Rad, which develops products for the life science research and clinical diagnostic markets, filed the lawsuit in the U.S. District Court for the District of Delaware. The patent involved in the suit covers techniques for detecting enzymatic reactions in microfluidic droplets.

The lawsuit is the second action Bio-Rad has filed against 10X Genomics directed at the latter's Next GEM products and the third action filed against the company overall.

In November 2018, a Federal District Court jury found that certain products sold by 10X Genomics willfully infringed three U.S. patents Bio-Rad licensed from the University of Chicago. The jury awarded Bio-Rad $23.9 million in damages.

In August, the Delaware Court also awarded Bio-Rad an additional $10.5 million in supplemental damages and interest and ordered 10X Genomics to refrain from selling the infringing products.

Meanwhile, on Sept. 3, 10X Genomics upsized its planned IPO on the Nasdaq. The company plans to raise about $271 million in a sale of 9 million class A shares.